Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Apr;41(4):735-8.
doi: 10.3899/jrheum.130847. Epub 2014 Feb 15.

Colchicine in Behçet syndrome: a longterm survey of patients in a controlled trial

Vedat Hamuryudan  1 , Gulen Hatemi, Koray Tascilar, Sebahattin Yurdakul, Cem Mat, Yilmaz Ozyazgan, Emire Seyahi, Serdal Ugurlu, Hasan Yazici
Affiliations
Randomized Controlled Trial

Colchicine in Behçet syndrome: a longterm survey of patients in a controlled trial

Vedat Hamuryudan et al. J Rheumatol. 2014 Apr.

Abstract

Objective: To test the hypothesis that colchicine use during early disease decreases immunosuppressive use in Behçet syndrome (BS) in the long term.

Methods: Patients with BS who participated in a double-blind, placebo-controlled trial of colchicine 16.6±1.1 years ago were evaluated for immunosuppressive use during the posttrial period.

Results: We could contact 90/116 patients; 28 (31%) received immunosuppressives during the posttrial period, 14 being from the colchicine arm. Posttrial colchicine use and cumulative duration were similar between patients who received immunosuppressives and those who did not.

Conclusion: Continuous use of colchicine, even when initiated at an early disease stage, does not seem to decrease the use of immunosuppressives in the long term.

Keywords: BEHÇET SYNDROME; COLCHICINE; PROGNOSIS.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources